Haemonetics Corporation
$ 80.28
0.34%
26 Dec - close price
- Market Cap 3,867,670,000 USD
- Current Price $ 80.28
- High / Low $ 80.44 / 79.41
- Stock P/E 23.47
- Book Value 18.16
- EPS 3.42
- Next Earning Report 2026-02-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.20 %
- 52 Week High 87.32
- 52 Week Low 47.32
About
Haemonetics Corporation (HAE), headquartered in Boston, Massachusetts, is a leading global healthcare company specializing in innovative medical products and solutions for blood and plasma collection, as well as surgical applications. With a strong commitment to enhancing patient care through advanced technologies, the company is strategically positioned to address the growing demands within the healthcare sector. Haemonetics emphasizes its dedication to improving patient outcomes, supported by robust investments in research and development that solidify its role as a key player in the evolving medical device market.
Analyst Target Price
$90.20
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-08 | 2023-11-02 | 2023-08-08 | 2023-05-11 | 2023-02-07 |
| Reported EPS | 1.27 | 1.1 | 1.24 | 1.19 | 1.12 | 1.02 | 0.9 | 1.04 | 0.99 | 1.05 | 0.77 | 0.85 |
| Estimated EPS | 1.11 | 1.02 | 1.22 | 1.17 | 1.07 | 1.01 | 0.89 | 0.94 | 0.89 | 0.73 | 0.7 | 0.82 |
| Surprise | 0.16 | 0.08 | 0.02 | 0.02 | 0.05 | 0.01 | 0.01 | 0.1 | 0.1 | 0.32 | 0.07 | 0.03 |
| Surprise Percentage | 14.4144% | 7.8431% | 1.6393% | 1.7094% | 4.6729% | 0.9901% | 1.1236% | 10.6383% | 11.236% | 43.8356% | 10% | 3.6585% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HAE
2025-12-22 03:09:24
Assenagon Asset Management S.A. has initiated a new position in Haemonetics Corporation with an investment of approximately $8.56 million, acquiring 175,574 shares. This move highlights significant institutional interest in Haemonetics, as institutional investors now own 99.67% of the company's stock. Analysts currently rate Haemonetics with a "Moderate Buy" and a consensus target price of $84.10, indicating positive outlook for the medical instruments supplier.
2025-12-18 07:09:24
Haemonetics (HAE) experienced a downgrade from Needham to 'Hold' due to increasing competition in vascular closure devices from Abbott and Cordis. Despite a recent 56% share price return over three months, the 5-year total shareholder return remains negative, questioning the durability of its Interventional Technologies growth story. The stock currently trades at a discount to analyst targets and intrinsic value, leading investors to weigh whether it is undervalued or if its current price already accounts for future growth amidst new competitive pressures.
2025-12-16 08:15:00
Riverwater Partners' Small Cap Strategy sold its stake in Haemonetics Corporation (HAE) during the third quarter of 2025. The strategy, which focuses on higher-quality companies, lagged its benchmark due to the market's preference for lower-quality companies. Investors can download the Q3 2025 investor letter for more details.
2025-12-16 04:10:57
Needham has downgraded Haemonetics (NYSE:HAE) from Buy to Hold due to increasing competition in the vascular closure device market, particularly from Abbott and Cordis. The firm projects a continued decline in Haemonetics' Interventional Technologies segment through fiscal year 2027, despite the company's "GREAT" financial health and recent strong earnings. This competitive pressure is expected to limit Haemonetics' future revenue and earnings per share growth, putting consensus estimates at risk.
2025-12-16 04:08:59
Baird has maintained its Outperform recommendation for Haemonetics (NYSE:HAE) as of December 15, 2025. The average one-year price target for HAE is $86.24, suggesting a 3.29% upside from its current price of $83.49 per share. Analyst forecasts for Haemonetics project annual revenue of 1,270MM (a 4.36% decrease) and non-GAAP EPS of 4.41.
2025-12-16 03:08:40
Needham has downgraded Haemonetics (NYSE:HAE) from Buy to Hold due to mounting competition in the vascular closure device market, particularly from Abbott (NYSE:ABT) and Cordis. The firm projects a continued decline in Haemonetics' Interventional Technologies segment through fiscal year 2027, despite the company's "GREAT" financial health score and recent strong earnings in its Plasma and Blood Management segments. This downgrade suggests that while other segments are performing well, sustained competitive pressure in a key area could limit future revenue and EPS growth, potentially impacting consensus estimates.
